文献速递衰弱、肌少症与跌倒多重用药

长期多重用药伴用药负担指数升高加重老年小鼠衰弱并损害躯体功能,撤药可减轻影响

Chronic Polypharmacy with Increasing Drug Burden Index Exacerbates Frailty and Impairs Physical Function, with Effects Attenuated by Deprescribing, in Aged Mice.
PubMed 文献 · J Gerontol A Biol Sci Med Sci · 2021-01-01

在12月龄雄性C57BL/6J小鼠中给予含多重用药或单药治疗(不同DBI评分)的饲料/饮水,21月龄时按衰弱分层分为继续治疗或撤药组,于12、15、18、24月龄评估衰弱与躯体功能。结果发现多重用药伴DBI升高及西酞普兰单药使小鼠更衰弱、活动减少、力量与功能活动受损,老年期撤药可逆转部分结局。

要点

  • 长期多重用药伴DBI升高可加重老年小鼠衰弱并损害躯体功能。
  • 西酞普兰单药同样导致衰弱、活动减少及力量与功能活动受损。
  • 老年期撤药可逆转部分不良结局,关键在药物类型与剂量而非药物数量。

核心结论

  • 长期多重用药伴DBI升高加重老年小鼠衰弱并损害躯体功能,老年期撤药可逆转部分结局。
  • 导致不良老年结局的是药物类型与剂量(DBI)而非药物数量(多重用药)。

研究设计与样本

  • 纵向临床前研究,12月龄雄性C57BL/6J小鼠接受对照饲料或含多重用药/单药(不同DBI评分)的饲料和/或饮水。
  • 21月龄时各治疗组按衰弱分层再分为终身继续治疗或撤药,于12、15、18、24月龄评估衰弱与躯体功能,采用混合模型分析。

主要发现

  • 多重用药伴DBI升高及西酞普兰单药使小鼠更衰弱、活动减少、力量与功能活动受损。
  • 老年期撤药可逆转部分上述结局。
  • 不良老年结局与药物类型和剂量(DBI)相关,而非药物数量。

临床怎么用

  • 对老年患者应关注药物类型与剂量(尤其抗胆碱能/镇静负荷,DBI)而非仅计数药物数量。
  • 在个体化评估获益与危害后,老年期撤药可能改善衰弱与躯体功能结局。

局限性

  • 为临床前动物研究,结论向人类外推需谨慎。
  • 原文未报告具体样本量、效应量及P值等统计细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Polypharmacy (use of ≥5 medications) and increasing Drug Burden Index (DBI) score (measure of person's total exposure to anticholinergic/sedative medications) are associated with impaired physical function in observational studies of older adults. Deprescribing, the supervised withdrawal of medications for which harms outweigh benefits for an individual, may be a useful intervention. Current knowledge is limited to clinical observational studies that are unable to determine causality. Here, we establish a preclinical model that investigates the effects of chronic polypharmacy, increasing DBI, and deprescribing on global health outcomes in aging. In a longitudinal study, middle-aged (12 months) male C57BL/6J (B6) mice were administered control feed or feed and/or water containing polypharmacy or monotherapy with different DBI scores. At 21 months, each treatment group was subdivided (stratified by frailty at 21 months) to either continue on treatment for life or to have treatment withdrawn (deprescribed). Frailty and physical function were evaluated at 12, 15, 18, and 24 months, and were analyzed using a mixed modeling approach. Polypharmacy with increasing DBI and monotherapy with citalopram caused mice to become frailer, less mobile, and impaired their strength and functional activities. Critically, deprescribing in old age reversed a number of these outcomes. This is the first preclinical study to demonstrate that chronic polypharmacy with increasing DBI augments frailty and impairs function in old age, and that drug withdrawal in old age reversed these outcomes. It was not the number of drugs (polypharmacy) but the type and dose of drugs (DBI) that caused adverse geriatric outcomes.

来源:J Gerontol A Biol Sci Med Sci,查看原文。版权归原作者所有。

引用

  1. Mach J, Gemikonakli G, Logan C, et al. Chronic Polypharmacy with Increasing Drug Burden Index Exacerbates Frailty and Impairs Physical Function, with Effects Attenuated by Deprescribing, in Aged Mice. J Gerontol A Biol Sci Med Sci. 2021. PMID: 32147704. doi:10.1093/gerona/glaa060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。